AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Precigen 2025 Q2 Earnings Significant Net Loss Reduction
Generated by AI AgentAinvest Earnings Report Digest
Wednesday, Aug 13, 2025 11:13 am ET1min read
Aime SummaryPrecigen reported its Q2 2025 earnings on August 12, showing a significant improvement in net loss compared to the same period in 2024. The results narrowly met expectations, though the company did not issue new financial guidance. The CEO highlighted a strategic focus on key clinical development, with no adjustments to financial forecasts.
Revenue
Total revenue for in Q2 2025 increased by 16.8% to $822,000, up from $704,000 in Q2 2024. Within the revenue breakdown, product sales contributed $41,000, while service revenue accounted for the majority at $781,000. Other revenue sources added $34,000, bringing the total revenue to $856,000. The performance across segments highlights a strong contribution from services, supported by a more diversified revenue stream.
Earnings/Net Income
Precigen narrowed its losses to $0.09 per share in Q2 2025, an improvement of 60.9% from a loss of $0.23 per share in the prior year. On the net income front, the company reduced its net loss to -$26.64 million, representing a 54.7% reduction from the $-58.79 million loss in Q2 2024. While the company remains unprofitable, the substantial reduction in losses is a positive sign.
Price Action
Precigen’s stock price rose 3.45% on the latest trading day, but dropped 6.74% over the most recent full trading week and edged down 1.64% month-to-date.
Post-Earnings Price Action Review
The strategy of purchasing Precigen shares after the revenue-positive quarter and holding for 30 days yielded a modest CAGR of 1.44%, underperforming the benchmark by 42.10%. Despite a maximum drawdown of 0.00% and a Sharpe ratio of 0.02, the strategy indicated minimal risk but limited returns, suggesting that post-earnings momentum did not strongly favor the stock.
CEO Commentary
Helen Sabzevari, CEO of Precigen, emphasized the company’s focus on its lead candidate, PRGN-2012, an AdenoVerse®-based HPV6/11 therapeutic vaccine for recurrent respiratory papillomatosis (RRP). The candidate has received FDA Priority Review with a PDUFA date of August 27, 2025. Sabzevari highlighted the clinical data, including a 51% complete response rate and an 86% reduction in surgical procedures, as significant progress. The CEO expressed cautious optimism about the regulatory pathway and the potential for commercial success in an underserved patient population.
Guidance
Precigen did not provide specific quantitative financial guidance for future periods but outlined a lean operating model and a strategic realignment that included over 20% workforce reductions. The company remains focused on supporting the potential commercialization of PRGN-2012 and key clinical and regulatory milestones.
Additional News
Within three weeks of the earnings report, Precigen did not announce any mergers, acquisitions, or significant C-level changes. The company also did not issue any dividend or share repurchase news. There were no notable corporate updates outside of its ongoing clinical development and strategic realignment efforts.
Revenue
Total revenue for in Q2 2025 increased by 16.8% to $822,000, up from $704,000 in Q2 2024. Within the revenue breakdown, product sales contributed $41,000, while service revenue accounted for the majority at $781,000. Other revenue sources added $34,000, bringing the total revenue to $856,000. The performance across segments highlights a strong contribution from services, supported by a more diversified revenue stream.
Earnings/Net Income
Precigen narrowed its losses to $0.09 per share in Q2 2025, an improvement of 60.9% from a loss of $0.23 per share in the prior year. On the net income front, the company reduced its net loss to -$26.64 million, representing a 54.7% reduction from the $-58.79 million loss in Q2 2024. While the company remains unprofitable, the substantial reduction in losses is a positive sign.
Price Action
Precigen’s stock price rose 3.45% on the latest trading day, but dropped 6.74% over the most recent full trading week and edged down 1.64% month-to-date.
Post-Earnings Price Action Review
The strategy of purchasing Precigen shares after the revenue-positive quarter and holding for 30 days yielded a modest CAGR of 1.44%, underperforming the benchmark by 42.10%. Despite a maximum drawdown of 0.00% and a Sharpe ratio of 0.02, the strategy indicated minimal risk but limited returns, suggesting that post-earnings momentum did not strongly favor the stock.
CEO Commentary
Helen Sabzevari, CEO of Precigen, emphasized the company’s focus on its lead candidate, PRGN-2012, an AdenoVerse®-based HPV6/11 therapeutic vaccine for recurrent respiratory papillomatosis (RRP). The candidate has received FDA Priority Review with a PDUFA date of August 27, 2025. Sabzevari highlighted the clinical data, including a 51% complete response rate and an 86% reduction in surgical procedures, as significant progress. The CEO expressed cautious optimism about the regulatory pathway and the potential for commercial success in an underserved patient population.
Guidance
Precigen did not provide specific quantitative financial guidance for future periods but outlined a lean operating model and a strategic realignment that included over 20% workforce reductions. The company remains focused on supporting the potential commercialization of PRGN-2012 and key clinical and regulatory milestones.
Additional News
Within three weeks of the earnings report, Precigen did not announce any mergers, acquisitions, or significant C-level changes. The company also did not issue any dividend or share repurchase news. There were no notable corporate updates outside of its ongoing clinical development and strategic realignment efforts.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
ConAgra Brands 2026 Q2 Earnings Sharp Net Loss Amid Revenue Decline and EPS Drop
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet